A Longitudinal Study to Identify IBS Phenotypes Using Fecal Microbiota and Hydrogen Breath Testing

Summary

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a highly prevalent but poorly understood condition with limited treatment options. Current therapies, including a nonabsorbable antibiotic rifaximin or diet low in fermentable oligosaccharides, disaccharides, monosaccharides, and polyols (FODMAP), show efficacy in 50% or less of patients. In this proposal, participants with IBS-D will be randomized to receive either rifaximin or low FODMAP dietary intervention.

Timeline

Start

2018-02-13

Primary completion

2024-02-28

Completion

2024-02-28

Publications

• Lee AA, Rao K, Singh P, Fehlman J, Gao J, Takakura W, Lynett A, Haller E, Ball S, Marand A, Liu A, Shah E, Menees S, Punglia R, Nojkov B, Eswaran S, Baker J, Chey WD, Owyang C, Young V, Hasler WL. A Randomized Trial of Rifaximin vs Low Fermentable Oligosaccharides, Disaccharides, Monosaccharides, and Polyols Diet for Symptom Outcomes and Microbiome Changes in Irritable Bowel Syndrome. Clin Gastroenterol Hepatol. 2026 Apr 21:S1542-3565(26)00316-2. doi: 10.1016/j.cgh.2026.04.014. Online ahead of print.

Drugs

Indications